ClinicalTrials.gg
RecruitingNCT06617897Updated Oct 13, 2026

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

A Phase 3 interventional study of CSL511 Fibrinogen concentrate (human) and Cryoprecipitate in Acquired Fibrinogen Deficiency, sponsored by CSL Behring. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.

02

Conditions studied

  • Acquired Fibrinogen Deficiency

Keywords

  • Fibrinogen deficiency
  • Pseudomyxoma peritonei
  • Cytoreductive surgery
  • Hyperthermic intraperitoneal chemotherapy
  • Blood coagulation disorder
03

In context

Afibrinogenemia

32 studies on the registry are indexed under Afibrinogenemia; 5 are open to participants now.

This study's planned enrollment of 90 is above the median of 40 across 19 interventional studies indexed under Afibrinogenemia.

Browse Afibrinogenemia studies →

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Aged >= 18 years at the time of providing written .
    • Diagnosis of PMP requiring CRS with HIPEC.
    • Bleeding risk: Predicted intraoperative blood loss of >=2L, assessed within 60 and 100 mins after start of study surgery (assessment made before 2 L of blood is lost)

Exclusion criteria

Exclusion Criteria:

    • Confirmed or suspected congenital or acquired coagulation disorder or a prothrombotic disorder
    • Myocardial infarction, acute coronary syndrome, or stroke within 2 months before study surgery.
    • Known history of chronic hepatitis.
    • Clopidogrel or ticagrelor administration within 5 days before study surgery.
    • Prasugrel administration within 7 days before study surgery.
    • Oral factor Xa inhibitor administration within 2 days before study surgery.
    • Glycoprotein IIb / IIIa antagonist administration within 24 hours before study surgery.
    • Oral direct thrombin inhibitor administration within 3 days before study surgery.
    • Vitamin K antagonists within 5 days before study surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    CSL511

    Biological: CSL511 Fibrinogen concentrate (human)

  • Active comparator
    Cryoprecipitate

    Biological: Cryoprecipitate

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants with overall hemostatic success

    Overall hemostatic success will be assessed by an independent data monitoring and efficacy adjudication committee (IDMEAC). The IDMEAC will assess the overall efficacy based on a composite of intraoperative and postoperative hemostasis using a 4-point scale, where ratings correspond to excellent or good (hemostatic success) or moderate or none (hemostatic failure).

    Time frame: During surgery to 24 hours after surgery

Secondary outcomes

  1. Number of participants with treatment-emergent (TE): adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs)

    The TE AESIs include thromboembolic events, viral transmission/seroconversion, and anaphylaxis and severe hypersensitivity/severe allergic reactions.

    Time frame: Up to 30 days after IV infusion

  2. Number of participants with intraoperative hemostatic efficacy

    Intraoperative hemostatic efficacy will be assessed by the surgeon and anesthesiologist using an objective 4-point hemostatic efficacy scale, where ratings correspond to excellent or good (hemostatic success) or moderate or none (hemostatic failure).

    Time frame: During surgery

  3. Number of participants with postoperative hemostatic efficacy

    Postoperative hemostatic efficacy will be assessed by a hematologist using an objective 4-point hemostatic efficacy scale, where ratings correspond to excellent or good (hemostatic success) or moderate or none (hemostatic failure).

    Time frame: Up to 24 hours after surgery

  4. Plasma fibrinogen concentration

    Time frame: During surgery, at the end of surgery and up to 24 hours after start of surgery

  5. Mean total dose of fibrinogen administered

    Time frame: During surgery, at the end of surgery and up to 24 hours after start of surgery

  6. Number of doses of fibrinogen administered

    Time frame: During surgery, at the end of surgery and up to 72 hours after start of surgery

  7. Duration of surgery

    Time frame: During surgery

  8. Intraoperative blood loss

    Time frame: During surgery

  9. Intraoperative requirements for blood products

    Blood products include fresh frozen plasma, red blood cells, and platelets.

    Time frame: During surgery

  10. Postoperative blood loss

    Time frame: Up to 48 hours after start of surgery

  11. Postoperative requirements for blood products

    Blood products include fresh frozen plasma, red blood cells, and platelets.

    Time frame: Up to 9 days after surgery

  12. Number of participants with reoperation (for bleeding)

    Time frame: Up to 30 days after surgery

  13. Number of participants with reoperation (for reasons other than bleeding)

    Time frame: Up to 30 days after surgery

  14. Duration of mechanical ventilation

    Time frame: Up to 30 days after surgery

  15. Duration of intensive care unit (ICU) stay

    Time frame: Up to 30 days after surgery

  16. Duration of hospital stay

    Time frame: Up to 30 days after surgery

  17. 21-day mortality

    Time frame: Up to 21 days after surgery

  18. In-hospital mortality

    Time frame: Up to 30 days after surgery

  19. Time between placing the investigational product (IP) order to administration

    The following time to event parameters will be assessed: time between when IP is ordered and when IP is ready to administer in the operating room and time between when IP is ordered and start of IP administration.

    Time frame: During surgery

  20. Prothrombin time and activated partial thromboplastin time

    Time frame: Up to 8 days after surgery

  21. Coagulation parameter profile

    The following coagulation parameter profiles will be assessed: thrombin generation marker, protein C and S, antithrombin and alpha 2-antiplasmin.

    Time frame: Up to 8 days after surgery

  22. Coagulation factor profile

    The following coagulation factor profiles will be assessed: fibrinogen, factor VIII (FVIII):C, von Willebrand ristocetin cofactor (VWF:Rco) and factor XIII (FXIII).

    Time frame: Up to 8 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2027 → Jun 2027 and completion Oct 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Oct 1, 2024
StartActual
Oct 1, 2024
Primary completionEst.
Jun 30, 2027was Sep 2027
CompletionEst.
Jun 30, 2027was Oct 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2027→Jun 30, 2027
Oct 13, 2026
Study completion
Oct 29, 2027→Jun 30, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Sep 1, 2027→Jun 30, 2027
    Study completion Oct 29, 2027→Jun 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06617897
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Oct 1, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Trial Registration Coordinator
Contact
clinicaltrials@cslbehring.com
+1 610-878-4697
Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Homo sapiens whole

Start the discussion